相关实验视频
Updated: Jul 16, 2025

04:33
Methods for Detecting Cough and Airway Inflammation in Mice
Published on: August 2, 2024
663
作为P2X3对抗剂的Gefapixant对耐火性亚托皮性咳的疗效
Yoshihisa Ishiura1, Shosaku Nomura1, Yuka Ishii1
1First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
International medical case reports journal
|September 11, 2023
概括
吉法皮克桑 (Gefapixant) 有效地治疗了一名患有因阿托皮性咳而导致慢性难治咳的患者. 这种P2X3抗剂为难以治疗的咳提供了新的治疗选择.
科学领域:
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
背景情况:
- 慢性难治性咳显著影响患者的生活质量.
- 亚托皮性咳是日本慢性耐火性咳的主要原因,涉及酸性气管支气管炎和C纤维过敏症.
- 吉法皮克桑 (Gefapixant) 是一种新的P2X3抗剂,已被批准用于耐火性咳.
研究的目的:
- 报告一例慢性耐火性亚托皮咳,成功用 gefapixant 治疗.
- 评估P2X3受体对抗作用在治疗无氧咳方面的潜力.
主要方法:
- 一个64岁的女性非吸烟者的案例研究,患有慢性不治不治的无性咳.
- 在现有药物治疗中添加 gefapixant (90 mg/天).
- 评估咳症状的改善情况.
主要成果:
- 患者在添加 gefapixant 后,她痛苦的咳显著改善.
- 尽管先前的多种治疗方法的部分疗效,但Gefapixant提供了缓解.
- 这表明P2X3抑制是一种可行的治疗策略.
结论:
- 与fefapixant一起的P2X3受体对抗是慢性耐火性亚托皮咳的潜在治疗方法.
- 需要进一步的研究来确定哪些慢性咳疾病受益于P2X3抑制.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
210
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
210
Dose-Response Relationship: Potency and Efficacy
4.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.5K
Antiasthma Drugs: Muscarinic Receptor Antagonists
337
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
337
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
197
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
197

